Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Change in Cash (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Change in Cash for 5 consecutive years, with -$11.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 4.72% to -$11.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$57.4 million, a 110.81% decrease, with the full-year FY2024 number at -$43.4 million, down 273.12% from a year prior.
  • Change in Cash was -$11.9 million for Q3 2025 at Werewolf Therapeutics, up from -$14.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $99.6 million in Q2 2021 to a low of -$23.9 million in Q2 2024.
  • A 5-year average of -$1.4 million and a median of -$11.1 million in 2022 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 378.99% in 2023; the steepest drop was 620.29% in 2023.
  • Werewolf Therapeutics' Change in Cash stood at -$12.9 million in 2021, then grew by 13.75% to -$11.1 million in 2022, then soared by 138.54% to $4.3 million in 2023, then plummeted by 375.71% to -$11.8 million in 2024, then fell by 0.46% to -$11.9 million in 2025.
  • Per Business Quant, the three most recent readings for HOWL's Change in Cash are -$11.9 million (Q3 2025), -$14.8 million (Q2 2025), and -$18.9 million (Q1 2025).